



# Rapid Access Atrial Fibrillation Clinics

Evaluation of pharmacist-physician models of care

#### Disclosures

In accordance with the policy of the Cardiac Society of Australia and New Zealand the following presenter has indicated that they have a relationship which in the context of their presentation, could be perceived as a real or apparent conflict of interest but do not consider that it will influence their presentation. The nature of the conflict is listed:

- Consulting fees received previously for Sanofi, Boehringer Ingelheim, Novarti
- Funding for the project was provided by Safer Care Victoria as part of the cardiovascular learning health network
- Results are yet to be peer-reviewed







# Current wait time for first appointment with general cardiology:







# Current wait time for first appointment with general cardiology:


224 days (IQR 47-284)





#### RAAF model of care









### **Evaluation steps**





Access



Assessment



**Treatment** 



Patient experience





#### Access



Total patients (April 2022 to November 2023)	274
Attendance statistics	
Median time from discharge to first appointment (IQR)	23 (18-32)
Median time from referral to first appointment (IQR)*	14 (9-20)
Median time between pharmacist and physician appointment <sup>b</sup> (IQR)	28 (14-40)
Median number of appointments per patient (IQR)	2 (1-3)





### Assessment




Total patients	274
Risk assessments	
Care-set completed	274 (100.0%)
Echocardiogram completed	216 (78.8%)
CHADSVA Assessment completed	270 (98.5%)
Median CHADSVA score (IQR)	2 (1-3)
HASBLED assessment completed	270 (98.5%)





# Anticoagulant utilisation









## Net promoter score



Total RAAF patients	274
Completed NPS follow up	156/274 (56.9%)
Mean NPS score (95% confidence interval)	9.06 (8.81-9.30)





<sup>\*</sup>Conventional content analysis also undertaken for written feedback delivered

### Next steps: Health economic analysis



#### **Cost effectiveness analysis**

Perspective: Healthcare system

Time horizon: 2 years

Method: Microsimulation (1-day cycle for stroke risk)

Comparator: Cloned dataset but using general cardiology wait times

Outcome: Stroke and bleeding





## Acknowledgements

Dr Jed Morton – PhD Supervisor

Prof Zanfina Ademi – PhD Supervisor

Prof Simon Bell – PhD Supervisor

Mrs Renee Dimond – Deputy Director Clinical Pharmacy Services

Ms Mardi Simmons – Clinic pharmacy technician

Dr Rasantha Kurruppumullage – Clinic Physician

Safer Care Victoria – funding









# Rapid Access Atrial Fibrillation Clinics

Evaluation of pharmacist-physician models of care